AML with Recurrent Genetic Abnormalities

AML with Recurrent Genetic Abnormalities — Trials · CancerIndex

Clinical trials

Registered studies

183 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 10
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 20%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (35)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07566585	Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation	withdrawn	Phase 1	0	BlueSphere Bio, IncINDUSTRY	1	Sep 10, 2026	clinicaltrials
NCT01548911	Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia	withdrawn	Phase 2	0	Wake Forest University Health SciencesOTHER	0	Jul 2, 2018	clinicaltrials